Want to see SEER full AI Analyst Report?
SEER Stock Chart & Stats
$2.00
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.00
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$1.55 - $2.41
Previous CloseN/A
Volume76.55K
Average Volume (3M)113.15K
Market Cap
$121.70M
Enterprise Value$70.28M
Total Cash (Recent Filing)$166.67M
Total Debt (Recent Filing)$23.03M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding55,315,983
10 Day Avg. Volume70,395
30 Day Avg. Volume113,152
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.41
Price to Sales (P/S)6.52
P/FCF Ratio-2.27
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue4.79
Enterprise Value/Gross Profit10.19
Enterprise Value/Ebitda-1.03
Forecast
1Y Price Target
$4.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.83
Revenue Forecast (FY)$17.05M
Bulls Say, Bears Say
Bulls Say
Strong Cash Position And Cost DisciplineA large cash balance plus a ~20% YoY reduction in operating expenses materially extends runway and reduces near-term dilution risk. This funding flexibility supports continued R&D, litigation/IP defense and commercialization investment while management pursues breakeven, a durable strength for 2–6 months.
Defensible Intellectual Property PortfolioA broad, defended patent estate and active enforcement create a structural barrier to low-cost imitators, supporting pricing power, consumable pull-through and potential licensing. Sustained IP wins can protect market share and justify long-term commercial investment even as competitors enter the space.
Growing Scientific Validation And Large Biobank PartnershipsRapidly expanding peer‑reviewed validation and population‑scale collaborations underpin durable demand for high‑throughput proteomics. Large biobank projects create sticky, repeat consumable usage and data network effects that support steady long‑term pull‑through and product adoption.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow signals the business is not yet self‑funding; even with large cash reserves, the company remains reliant on that buffer or external funding. This structural cash burn elevates execution risk if revenue growth and consumable pull‑through lag, pressuring long‑term viability.
Small, Volatile And Declining Revenue BaseA small, choppy and declining revenue base undermines scalability: fixed costs absorbability is low and forecasts are uncertain. Durable commercial progress is required to convert validation and partnerships into predictable consumable-driven revenue; until then margins and cash generation will remain fragile.
Compressed Gross Margins And Mix SensitivityCurrent gross margins are far below long‑term targets and highly sensitive to instrument/consumable mix and utilization. Achieving 70–75% requires sustained scale and favorable revenue mix; until scale is realized, margin compression will limit durable profitability and cash conversion.
Seer News
SEER FAQ
What was Seer’s price range in the past 12 months?
Seer lowest stock price was $1.55 and its highest was $2.41 in the past 12 months.
What is Seer’s market cap?
Seer’s market cap is $121.70M.
When is Seer’s upcoming earnings report date?
Seer’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Seer’s earnings last quarter?
Seer released its earnings results on May 13, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.005.
Is Seer overvalued?
According to Wall Street analysts Seer’s price is currently Undervalued.
Does Seer pay dividends?
Seer does not currently pay dividends.
What is Seer’s EPS estimate?
Seer’s EPS estimate is -0.27.
How many shares outstanding does Seer have?
Seer has 55,315,983 shares outstanding.
What happened to Seer’s price movement after its last earnings report?
Seer reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -1.13%.
Which hedge fund is a major shareholder of Seer?
Currently, no hedge funds are holding shares in SEER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (100.00% Upside)
$4.00 (100.00% Upside)
Hedge Fund Trend
Decreased
By 15.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.34%
12-Months-Change
Fundamentals
Return on Equity
-26.58%
Trailing 12-Months
Asset Growth
-21.63%
Trailing 12-Months
Company Description
Seer
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
SEER Company Deck
SEER Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear short-term commercial and margin headwinds (33% YoY revenue decline, compressed gross margin to 35%, negative free cash flow) with multiple strategic positives: rapidly expanding scientific validation (publications doubled YoY), major population-scale biobank partnerships (PRECISE-SG100K and others), continued product and analytics innovation (SP200, Proteograph One Assay, next-gen detector, Raviant DIA), meaningful operating expense reductions (~20% YoY), improved net loss, strong cash position ($219.5M) and active share repurchases. Management reaffirmed full-year guidance and is taking defensive IP/legal actions against imitators while adding seasoned commercial leadership to drive commercialization. Overall, the call signals durable long-term opportunity and disciplined financial management but acknowledges near-term revenue and margin pressures.View all SEER earnings summariesSEER Stock 12 Month Forecast
Average Price Target
$4.00
▲(100.00% Upside)
Technical Analysis
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
TScan Therapeutics
―
Cognition Therapeutics
―
Ownership Overview
11.83% Insiders
6.19% Mutual Funds
0.25% Other Institutional Investors
77.69% Public Companies and
Individual Investors